Skip to main content
. 2021 Jul 20;13(7):1406. doi: 10.3390/v13071406

Figure 1.

Figure 1

Reolysin exhibits anticancer efficacy against HuT-78 and KARPAS-299 TCL cells. (A) Effects of Reolysin on TCL cell viability. TCL cells were treated with the indicated concentrations of Reolysin for 72 h. Cell viability was measured by MTT assay. Mean ± SD, n = 3; (B,C) Reolysin induces DNA fragmentation in HuT-78 and KARPAS-299 TCL cells. TCL cells were treated with the indicated concentrations of Reolysin for 48 h. Induction of apoptosis was measured by PI-FACS analysis. Representative histograms are presented in untreated (Control) cells and cells treated with 900 PFU/cell Reolysin for 48 h. (D,E) Reolysin induces active caspase-3 in HuT-78 and KARPAS-299 cells. Cells were treated with the indicted concentrations of Reolysin for 48 h, and active caspase-3 levels were determined by active caspase-3 fluorescent staining followed by flow cytometry. Representative histograms are presented in untreated (Control) cells and cells treated with 900 PFU/cell Reolysin for 48 h. Mean ± SD, n = 3.